Standard Treatment with Bevacizumab as Targeted Therapy in Cervical Cancer
ABSTRACT Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient’s quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Digital revista |
| Langue: | English |
| Publié: |
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2020
|
| Accès en ligne: | http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0034-83762020000400213 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|